What's Driving Day One's Recent Surge? The Servier Acquisition Explained.

Related Articles

What Does Servier's $2.5 Billion Acquisition Mean for Day One Biopharmaceuticals

5 months ago

What Just Happened with Day One Biopharmaceuticals and Servier

5 months ago

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

5 months ago

What's Driving AltC Acquisition's Recent Surge

3 months ago

Category

You may also like

Stock News•1 months ago

Breakfast News: Vertex Bets $10B to Win $5B a Year

Vertex acquired Crinetics for ~$10B, targeting a potential $5B annual revenue opportunity in endocrine therapies.

META

Share

Stock News•1 months ago

What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?

AbbVie's market cap rose ~$43B (~11%) in the past week, driven by acquisitions, new drug approvals, and pipeline expansion that bolstered long-term growth confidence.

ABBV

Share

Stock News•2 months ago

Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced

Syndax Pharmaceuticals' Q1 2026 net sales exceeded $100M, driven by Revuforj and Niktimvo, after transitioning into a two-product commercial oncology company with strong cash reserves.

SNDX

Share

Stock News•2 months ago

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

Edgewise Therapeutics shares surged 18% to a record high after the company announced a $2.65 billion neuromuscular business divestiture to Servier. The deal allows Edgewise to sharpen its strategic fo...

EWTX

Share